Minerva Neurosciences (NasdaqCM:NERV) Earnings Call Presentation
From Unmet Need to Reality Roluperidone is Potentially the First Treatment for Negative Symptoms of Schizophrenia KOL Event I February 3, 2026 1 Forward-Looking Statement This presentation contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward- looking statements are statements that are not historical facts, reflect management's expectations as of the date of this presentation, and involve certain risks ...